Market news

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will host a press conference and live webcast Wednesday, Sept. 16, 2026, at 10:30 a.m. Eastern Time.

Detailed price information for Co-Diagnostics Inc (CODX-Q) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Moby summary of Co-Diagnostics, Inc.'s Q2 2026 earnings call

Co-Diagnostics Inc (CODX) narrows Q2 2026 net loss to $6.3 million while advancing key regulatory submissions for its flu/RSV panel and tuberculosis test.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the second quarter ended June 30, 2026.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief

Co-Diagnostics Inc., a molecular diagnostics firm, announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., shipped evaluation kits of its SARAGENE Bundibugyo Virus Test to an independent testing facility. The distribution was initiated at the behest of the India...

Co-Diagnostics Inc. (NASDAQ:CODX), a molecular diagnostics firm, announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., shipped evaluation kits of its SARAGENE Bundibugyo Virus Test to an independent testing facility. The distribution was initiated at the behest of the India Center for Cellular and Molecular Platforms (C-CAMP), an initiative backed by the India Department of Biotechnology. Expanding Point-Of-Care Diagnostics For Virus Testing Alongside deploying these test kits,

Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evaluation and completing a new assay study.

Co-Diagnostics' India joint venture CoSara has started clinical studies for its rapid TB PCR test, advancing deployment of its point-of-care platform.

Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro instrument. The molecular diagnostics company said the initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform, following the company’s previously announced shipment of PCR Pro instruments, mycobacterium tuberculosis (TB or MTB) test kits and proprietary sample preparati

Co-Diagnostics (CODX) said Wednesday that its CoSara Diagnostics joint venture in India is initiatin

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the United Nations Office for Project Services' (UNOPS) Global Implementation Workshop on Near Point of Care (NPOC) TB Diagnostics in Bangkok, Thailand, July 8-10, 2026.